Ibrutinib (PCI-32765)

For research use only. Not for use in humans.

製品コードS2680

CAS No. 936563-96-1

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

サイズ

価格(税別)

在庫

10mM (1mL in DMSO)	JPY 47100	あり
5mg	JPY 30200	あり
50mg	JPY 163000	あり
200mg	JPY 412000	あり

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(411)

製品安全説明書

Target Protein Ligand阻害剤の選択性比較

生物活性

製品説明

ターゲット

BTK ^[1] (Cell-free assay)	BLK ^[1] (Cell-free assay)	Bmx ^[1] (Cell-free assay)	CSK ^[1] (Cell-free assay)	FGR ^[1] (Cell-free assay)	もっとクリックする
0.5 nM	0.5 nM	0.8 nM	2.3 nM	2.3 nM	もっとクリックする

体外試験

Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively. ^[1] Ibrutinib exhibits a significant dose-dependent and time-dependent induction of cytotoxicity in chronic lymphocytic leukemia (CLL) cells. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling. ^[2] A recent study shows that Ibrutinib inhibits BCR-activated primary B cell proliferation with IC50 of 8 nM and results in inhibition of TNFα, IL-1β and IL-6 production in primary monocytes with IC50 of 2.6 nM, 0.5 nM and 3.9 nM, respectively. ^[3]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human Rec1 cells	NInCUJFHfW6ldHnvckBie3OjeR?=	M{LjZ\|IvPSEQvF2=	M3y2OVYhcA>?	MkXaTY5pcWKrdHnvckBw\iCOeX6gdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGLlZ\|Eh[2WubIOgZZQhOi53IIXNJIlv[3WkYYTl[EBnd3JiNjDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCvZYToc4Q>	NILhVVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNlg4Pyd-MkWyNlI5Pzd:L3G+
human WSU-NHL cells	MkP0R5l1d3SxeHnjxsBie3OjeR?=		NG\zWIk4OiCq	M2[wUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHdUXS2QSFygZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6wPUDPxE1?	NXLiVphWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
human SU-DHL6 cells	M3;5cGN6fG:2b4jpZ:Kh[XO\|YYm=		M1LIXFczKGh?	MknER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV3UuTEiONjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkW4JO69VS5?	NFzvNlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
human DOHH2 cells	Mlq3R5l1d3SxeHnjxsBie3OjeR?=		MWS3NkBp	NUDPcVZCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTE:KSEKgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD60NUDPxE1w	NXnTSFhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 cells	MYPGeY5kfGmxbjDhd5NigQ>?		NXfscndKOSCq	M{HXOGlvcGmkaYTpc44hd2ZiTGnOMWEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDh[pRmeiB4MDDtbY5{KGK7IGTSMWZTTVRiQYPzZZktKEmFNUC9NE4zKM7:TT6=	Mm[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUi1OFcoRjJzOUW4OVQ4RC:jPh?=
human Ramos cells	NXfFfFFUTnWwY4Tpc44h[XO\|YYm=		NUHMU\|RwOSCq	MkXZTY5pcWKrdHnvckBw\iCEdHugbY4hcHWvYX6gVoFud3NiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBRVENvZ3HtcYEzKHCqb4PwbI9zgWyjdHnvckBifCCWeYKxNlE4KGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{NCCLQ{WwQVE1KG6PLh?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
human Pfeiffer cells	NF\BcW1HfW6ldHnvckBie3OjeR?=		M1PkNlczKGh?	MnS0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVIZmcW[oZYKgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MjDuUU4>	MoHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
Sf9 cells	NWPsZmVmTnWwY4Tpc44h[XO\|YYm=		NF;k[4wyKGh?	MVnJcohq[mm2aX;uJI9nKGi3bXHuJIZ2dGxvbHXu[5RpKEKWSzDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KHW\|aX7nJGZCVS2VcnP0bYRmKHCncITp[IUh[XNic4Xid5Rz[XSnIHHmeIVzKDZyIH3pcpMh[nliVGKtSnJGXCCDc4Phfg+9lCCLQ{WwQVAvPSCwTT6=	NVPpT2lMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
Sf9 insect cells	MXTGeY5kfGmxbjDhd5NigQ>?		NI\IOJg3OCCvaX7z	MXfJR\|UxKD1iMD6wNFA{KM7:TR?=	M1fTU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
sf9 cells	NEL5NIZHfW6ldHnvckBie3OjeR?=			NGnCfo5KSzVyIE2gNE4xODB\|IN88US=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOkc,Ojd7OUS3N\|Y9N2F-
Sf9 insect cells	MnTBSpVv[3Srb36gZZN{[Xl?		MY[2NEBucW6\|	NEiwfGpKSzVyIE2gNE4xODB\|NDFOwG0>	MoO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUKxO\|UoRjJ5OUGyNVc2RC:jPh?=
Sf9 insect cells	MXjGeY5kfGmxbjDhd5NigQ>?		M370W\|YxKG2rboO=	NV25PYJbUUN3MDC9JFAvODByM{Sg{txO	NXrPU3gxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|I6PDZpPkK4OFMzQTR4PD;hQi=>
Sf9 insect cells	NUW0PFJyTnWwY4Tpc44h[XO\|YYm=		NHr3dog3OCCvaX7z	NImyTGxKSzVyIE2gNE4xODB\|NDFOwG0>	NFr1TXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m1OlA{Pyd-Mke5OVYxOzd:L3G+
Sf9 cells	NInIZWtHfW6ldHnvckBie3OjeR?=		MUK2NEBucW6\|	NFPLemdKSzVyIE2gNE4xODB2IN88US=>	NWrwfFlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR\|PD;hQi=>
Sf9 cells	NVeyPI0zTnWwY4Tpc44h[XO\|YYm=		NVzZelA4PjBibXnudy=>	M1LhVmlEPTBiPTCwMlAxODVizszN	NWXjcYFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
Ramos cells	NVHlVpZCTnWwY4Tpc44h[XO\|YYm=		MkXyNUBp	NGPwPXhKSzVyIE2gNE4xODB3IN88US=>	NUTCc5BDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
Sf9 cells	M4K5V2Z2dmO2aX;uJIF{e2G7		NEnyeVI3OCCvaX7z	MnTWTWM2OCB;IECuNFAyKM7:TR?=	NHXqe489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3O\|YxQCd-M{CwO\|c3ODh:L3G+
Pfeiffer cells	MoC3R5l1d3SxeHnjbZR6KGG\|c3H5		NGSydVI4OiCq	NHnyS5hIUTVyIE2gNE4xODJizszN	M{nB[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
B cells	M3;lUGZ2dmO2aX;uJIF{e2G7		Mly0NUBp	MnrHTWM2OCB;IECuNFA1PiEQvF2=	MmfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OUC5PFgoRjNyMkmwPVg5RC:jPh?=
Sf9 insect cells	MmS1SpVv[3Srb36gZZN{[Xl?		MVmyJJRwKDZyIH3pcpM>	NVuwZ\|FCU2liPTCwMlAxPDhizszN	M2L0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
Ramos cells	NXf3WHplTnWwY4Tpc44h[XO\|YYm=		MV6xJIg>	MX;JR\|UxKD1iMD6wNFc2KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
Sf9 insect cells	M3HTTmZ2dmO2aX;uJIF{e2G7		NHLQTJo3OCCvaX7z	NWn0S5gxUUN3MDC9JFAvODB6IN88US=>	NV;rS\|BjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N\|E2PTl5PD;hQi=>
TMD8 cells	M2fwOGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MlvPO\|IhcA>?	NU[zbZNMUUN3MDC9JFAvODFizszN	NIK2XGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUexOVAzOyd-Mkm3NVUxOjN:L3G+
CD19+ B cells	MWTGeY5kfGmxbjDhd5NigQ>?		Mln1NUBp	NF3WZYNKSzVyIE2gNE4xOTJizszN	NUn6d4luRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVc6QDJpPkK5OFU4QTh{PD;hQi=>
Sf9 insect cells	MXnGeY5kfGmxbjDhd5NigQ>?		M1OwSVYxKG2rboO=	M4D1T2lEPTBiPTCwMlAyOiEQvF2=	NFjl[4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells	Mon4SpVv[3Srb36gZZN{[Xl?		MUOxJIg>	NHPXXodKSzVyIE2gNE4xOTRizszN	Mn7iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
Sf9 insect cells	Ml\USpVv[3Srb36gZZN{[Xl?		NH7Vb2wyKGh?	NUO0[oI5UUN3MDC9JFAvODF2NDFOwG0>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdzNUCyN{c,Ojl5MUWwNlM9N2F-
Sf9 insect cells	NW\ueXZmTnWwY4Tpc44h[XO\|YYm=		NFTBcFE3OCCvaX7z	NWHpT\|dGUUN3MDC9JFAvODF4MTFOwG0>	M4W1cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
HCC827 cells	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M4nNVlczKGh?	NWjUVGJ1UUN3MDC9JFAvODN7IN88US=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd\|NEW4NUc,Ojh5M{S1PFE9N2F-
PC9 cells	NHS1UoVHfW6ldHnvckBie3OjeR?=		M2DJTFczKGh?	NIfhXXRIUTVyIE2gNE4xPSEQvF2=	M4LhU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
Sf9 cells	NEHGb4RHfW6ldHnvckBie3OjeR?=		NV3Hd\|NVPjBibXnudy=>	NV7PU4FpUUN3MDC9JFAvOSEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNkG0N{c,OzByME[xOFM9N2F-
H3255 cells	NGTDV3BHfW6ldHnvckBie3OjeR?=		NGe2d204OiCq	M2nNWGdKPTBiPTCwMlEyKM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BaF3 cells	MlzHSpVv[3Srb36gZZN{[Xl?		Mo\ZO\|IhcA>?	MYjHTVUxKD1iMD6xNkDPxE1?	Ml:1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4M{C1OVMoRjJ4NkOwOVU{RC:jPh?=
BAF3 cells	NVPaVlMzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MUC3NkBp	M3LucWdKPTBiPTCwMlEzKM7:TR?=	NVTuW\|RmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
Sf9 insect cells	MUfGeY5kfGmxbjDhd5NigQ>?		M3\SSFYxKG2rboO=	NWj5R3M1UUN3MDC9JFAvOTJ\|IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
Sf9 insect cells	NFPwfoNHfW6ldHnvckBie3OjeR?=		MUO2NEBucW6\|	MUTJR\|UxKD1iMD6xOFYh\|ryP	NI[weXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
BAF3 cells	MWnGeY5kfGmxbjDhd5NigQ>?		M4DG[VczKGh?	NUTaZWg6T0l3MDC9JFAvOTZizszN	MkHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
Sf9 cells	MWTGeY5kfGmxbjDhd5NigQ>?		NFi5eJc3OCCvaX7z	NWf3emNqUUN3MDC9JFAvOiEQvF2=	M4XBNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUW4OVQ4Lz5{MUm1PFU1PzxxYU6=
MV411 cells	M{i4fmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MWXHTVUxKD1iMD6yOUDPxE1?	NIS0PGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
MV4-11 cells	NX:3SXlxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NH60OWI4OiCq	MnLNS2k2OCB;IECuN\|Mh\|ryP	MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4M{C1OVMoRjJ4NkOwOVU{RC:jPh?=
MV4-11 cells	MkTtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M1;3eVczKGh?	NWnWfVBHT0l3MDC9JFAvOzNizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
DOHH2 cells	NUX3UGFDS3m2b4TvfIlkcXS7IHHzd4F6		NHvwV4M4OiCq	M3foZ2dKPTBiPTCwMlQyKM7:TR?=	NHfGelA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
HCC827 cells	NXr4RVNqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NF3nZZg6PiCq	MkT1SWM2OCB;IECuOFUh\|ryP	NUPWdY5ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
SU-DHL6 cells	Ml7ZR5l1d3SxeHnjbZR6KGG\|c3H5		M2ftTVczKGh?	M2q4U2dKPTBiPTCwMlU5KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
M07e cells	NYT2OZQ6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NVHzXVVqT0l3MDC9JFAvPTlizszN	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
NCI-H1975 cells	Mne4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NIPm[5g6PiCq	M3HWOGVEPTBiPTCwMlY1KM7:TR?=	MlLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
SU-DHL-2 cells	NEX5W\|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NWLGfGIyT0l3MDC9JFAvPjRizszN	NFTGT4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
HEK293T cells	M1ToSWZ2dmO2aX;uJIF{e2G7		NVzPOot7OSCq	NXfkVpJlUUN3MDC9JFAvQSEQvF2=	NI\QZXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
Ramos cells	NWHXWYdbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MoHQO\|IhcA>?	NF;EfYlKSzVyIE2gNE46OiEQvF2=	MlrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5MUWwNlMoRjJ7N{G1NFI{RC:jPh?=
BA/F3 cells	Ml\JRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M3LRN\|czKGh?	NUjPUG5WUUN3MDC9JFEh\|ryP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3OEWyNUc,OjZ{NUi1NlE9N2F-
WSU-NHL cells	NVfDWVdlS3m2b4TvfIlkcXS7IHHzd4F6		MV:3NkBp	NWLRZ4RoT0l3MDC9JFEvODlizszN	NHrKd3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
NCI-H1975 cells	MoHYSpVv[3Srb36gZZN{[Xl?		MlPjO\|IhcA>?	NW[3ZWR6T0l3MDC9JFEvOiEQvF2=	MnW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975 cells	NUnOcos1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M1XOR\|czKGh?	Ml[yTWM2OCB;IEGuNlch\|ryP	M2LLbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{O0OVgyLz5{OEezOFU5OTxxYU6=
Raji cells	NHfqRlhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NV7FfJgyPDhiaB?=	NUjITox3UUN3MDC9JFEvPDlizszN	NX\SSI9pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OlczQTVpPkK5OVY4Ojl3PD;hQi=>
Pfeiffer cells	M3\TT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NEL1VG9IUTVyIE2gNU43KM7:TR?=	NVyyXpdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N\|E2PTl5PD;hQi=>
A431 cells	NEDwUYdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M{fJ[Fk3KGh?	MUXFR\|UxKD1iMj6zPEDPxE1?	M{PRclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
BAF3 cells	M{nxNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MVK3NkBp	M{TBSmdKPTBiPTCyMlUh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
U937 cells	MnvKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MlT0S2k2OCB;IEKuPUDPxE1?	MkHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
NB4 cells	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NXjBPIIxT0l3MDC9JFMh\|ryP	NWXpWVBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N\|E2PTl5PD;hQi=>
Ramos cells	NILzOZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MYfHTVUxKD1iMz60JO69VQ>?	NYHtN2hlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N\|E2PTl5PD;hQi=>
SKM1 cells	NHXERpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NGT0fW9IUTVyIE2gN{43KM7:TR?=	MnXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
U2932 cells	M1PNXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M4K0e2dKPTBiPTC0MlQh\|ryP	MlXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
Ramos cells	NHfhU4pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MkDCO\|IhcA>?	M323TmlEPTBiPTC1MlE1KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNkG0N{c,OzByME[xOFM9N2F-
Ramos cells	NXnCXoNOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MVW0PEBp	Mn3FTWM2OCB;IEWuNVQh\|ryP	M4rVRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUW2NFM4Lz5{N{m1OlA{PzxxYU6=
Ramos cells	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MWC0PEBp	M3PBVmlEPTBiPTC1Mlg5KM7:TR?=	MlnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{K5OFYoRjJ6NEOyPVQ3RC:jPh?=
Ramos cells	Ml7iRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MYO3NkBp	Ml7tTWM2OCB;IE[uOlIh\|ryP	M3\JXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
K562 cells	NXPmS\|lESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M2nROFQ5KGh?	M{fsS2lEPTBiPTC3MlUh\|ryP	M1zWfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5\|MEC3O\|YxQDxxYU6=
HL60 cells	NVTacnZbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NGjpXYo1QCCq	NUS1[mVqUUN3MDC9JFgh\|ryP	M3y3RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5\|MEC3O\|YxQDxxYU6=
Ramos cells	MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MWe0PEBp	MW\JR\|UxKD1iOD6xNUDPxE1?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOkc,Ojd7OUS3N\|Y9N2F-
Ramos cells	NHe5TVBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NFTodG81QCCq	M17JVGlEPTBiPTC4MlI3KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV4N{K5OUc,Ojl3NkeyPVU9N2F-
OCI-AML3 cells	NX7q[XZQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M3fpeWdKPTBiPTC5MlIh\|ryP	M1jGN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
BAF3 cells	MofTR5l1d3SxeHnjbZR6KGG\|c3H5		MV63NkBp	NXmxcpZtT0l3MDC9JFExKM7:TR?=	M1riSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkOwOVU{Lz5{Nk[zNFU2OzxxYU6=
BAF3 cells	M{LtO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NVr0OnZOPzJiaB?=	NUftOHdbT0l3MDC9JFExKM7:TR?=	M4LiblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3 cells	NYDXPJQ6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXW3NkBp	NFjWdm1IUTVyIE2gNVAh\|ryP	NVLleJVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NAMALWA cells	MnvlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M3P1N\|czKGh?	M2fpXGlEPTBiPTCxNE41PSEQvF2=	NV;XNGlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFYyOzZpPkK5NVQ3OTN4PD;hQi=>
Ramos cells	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MXO0PEBp	NWnYbm5MUUN3MDC9JFEzNjZizszN	M4LDbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Raji cells	M4rDVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M1Hab\|Q5KGh?	NEPGZ5dKSzVyIE2gNVQvOiEQvF2=	M{DXflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5\|MEC3O\|YxQDxxYU6=
Raji cells	NYDGNWhDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MUC0PEBp	M1LZdWlEPTBiPTCxOU4zKM7:TR?=	M4\QblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O\|M3Lz5{N{m5OFc{PjxxYU6=
MIAPaCa2 cells	NVy3WGhUS3m2b4TvfIlkcXS7IHHzd4F6		M4jseVMh\GG7cx?=	NV\kVpZVUUN3MDC9JFE3NjZizszN	M17OWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEe3NlI5Lz5{N{C3O\|IzQDxxYU6=
HeLa cells	M2\4WGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MorIN{Bl[Xm\|	M17JNGlEPTBiPTCxOk45KM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
Raji cells	NF;wcY1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M1;KUFQ5KGh?	NUjJVlFtUUN3MDC9JFE6NjNizszN	M1HNbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Raji cells	MmXqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MXe0PEBp	MYHJR\|UxKD1iMUmuN{DPxE1?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|Mkm0Okc,Ojh2M{K5OFY9N2F-
Raji cells	MnqxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		Ml;EO\|IhcA>?	NX;OSlVKUUN3MDC9JFE6NjVizszN	NWT1UGd7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR\|PD;hQi=>
Raji cells	M13BO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NInkOFI1QCCq	M4TkVWlEPTBiPTCxPU42KM7:TR?=	NVPHSZlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5OVYxOzdpPkK3PVU3ODN5PD;hQi=>
NAMALWA cells	NYjiOoxzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M3LYNVczKGh?	MX;JR\|UxKD1iMUmuOkDPxE1?	NWPPe5A5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR\|PD;hQi=>
A2780 cells	MkTwR5l1d3SxeHnjbZR6KGG\|c3H5		NXLtXIRvOyCmYYnz	M3npSWVEPTBiPTCyNE4yKM7:TR?=	NEC2U5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C3O\|IzQCd-MkewO\|czOjh:L3G+
Raji cells	MlHFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M4H1U\|czKGh?	NILhcIRKSzVyIE2gNlAvQDhizszN	NHfpeI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0OlE{Pid-MkmxOFYyOzZ:L3G+
A549 cells	NGPsOFVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NYHCSndsPzJiaB?=	M2jhTmlEPTBiPTCyNU44QSEQvF2=	Mk[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{S1PFEoRjJ6N{O0OVgyRC:jPh?=
SW480 cells	M17vUWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M4XWVFMh\GG7cx?=	MUDJR\|UxKD1iMkWuOkDPxE1?	NGXnZms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C3O\|IzQCd-MkewO\|czOjh:L3G+
Ramos cells	Ml3UR5l1d3SxeHnjbZR6KGG\|c3H5		M2nFblI1KGh?	NYn5XXh2UUN3MDC9JFI5NjdizszN	MmK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{N{S2O\|UoRjJ6Mke0Olc2RC:jPh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	pEGFR(Tyr1068) / EGFR; PubMed: 28061447 Oncotarget Ibrutinib inhibitory effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment. pBTK / pPLCγ2 / pAKT / pERK / pJNK; PubMed: 23940282 Blood Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCγ2, pAKT, pERK, and pJNK.	28061447 23940282
Immunofluorescence	CD11b; PubMed: 30231870 J Neuroinflammation BV2 microglial cells were pretreated with ibrutinib (1 μM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with an anti-CD11b antibody. Scale bar = 20 μm. COX-2; PubMed: 30231870 J Neuroinflammation BV2 microglial cells were treated with vehicle (1% DMSO) or ibrutinib (1 μM) for 30 min, followed by PBS or LPS (1 μg/ml) for 5.5 h, and immunocytochemistry was conducted with anti-CD11b and anti-COX-2 antibodies.	30231870
ELISA	hTNFα; PubMed: 26627823 J Biol Chem PBMs were isolated and pretreated with 1, 5, or 10 μm ibrutinib (IB) or left untreated (UT, −). Pretreated PBMs were incubated for 24 h in 96-well plates precoated without (PBS) or with 10 μg/ml whole human IgG. Cleared supernatants were collected and analyzed by ELISA for TNFα (n = 3). IL-10; PubMed: 27792904 Virology LMP2A-negative (vector.1/.2) and -positive (express LMP2A) B cell lines were incubated in the absence or presence of increasing concentrations of Ibrutinib for 24 hours and supernatants were isolated for analysis using an IL-10 ELISA.	26627823 27792904

体内試験

In a collagen-induced arthritis model, Ibrutinib significantly reduces clinical arthritis scores reflecting paw swelling and joint inflammation by inhibiting B-cell activation. In a MRL-Fas(lpr) lupus model, Ibrutinib reduces renal disease and autoantibody production. ^[1] In an adoptive transfer TCL1 mouse model of CLL, Ibrutinib (25 mg/kg/day) causes a transient early lymphocytosis, and delays CLL disease progression. ^[4]

お薦めの試験操作（参考用のみ）

キナーゼ試験： ^[1]	- 合併 Kinase Assays : In vitro kinase IC50 values are measured using ³³P filtration binding assay after 1 hour incubation of kinase, ³³P-ATP, Ibrutinib, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays are performed at Reaction Biology.
細胞試験： ^[2]	- 合併細胞株： Chronic lymphocytic leukemia (CLL) cells 濃度： 0.01-100 μM 反応時間： 48 hours 実験の流れ： MTT (3'[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assays are performed to determine cytotoxicity. Briefly, cells (CLL B cells or healthy volunteer T cells or NK cells) are incubated for 48 hours with different concentrations of Ibrutinib, or vehicle control. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. Dimethyl sulfoxide is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed with Expo-ADC32 software package. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis includes the addition of 100μM Z-VAD. (参考用のみ)
動物試験： ^[1]	- 合併動物モデル： MRL-Fas(lpr) lupus model and collagen-induced arthritis model. 投薬量： ≤50 mg/kg 投与方法： Administered via p.o. (参考用のみ)

参考

[4] Ponader S, et al. Blood. 2012, 119(5), 1182-1189.

- 合併

溶解度 (25°C)

体外	DMSO	88 mg/mL (199.77 mM)
	Ethanol	45 mg/mL (102.15 mM)
	Water	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O 混合させたのち直ちに使用することを推奨します。	10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Ibrutinib (PCI-32765) SDFをダウンロードする

分子量	440.5
化学式	C₂₅H₂₄N₆O₂
CAS No.	936563-96-1
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	N/A
Smiles	C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04294641	Recruiting	Drug: Ibrutinib	Chronic GVHD	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	January 5 2021	Phase 2
NCT04665115	Not yet recruiting	Drug: Ibrutinib\|Other: Quality-of-Life Assessment	Asymptomatic COVID-19 Infection Laboratory-Confirmed\|B-Cell Neoplasm\|Chronic Lymphocytic Leukemia\|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma\|Mantle Cell Lymphoma\|Marginal Zone Lymphoma\|Small Lymphocytic Lymphoma\|Symptomatic COVID-19 Infection Laboratory-Confirmed\|Waldenstrom Macroglobulinemia	Academic and Community Cancer Research United\|National Cancer Institute (NCI)	December 31 2020	Phase 2
NCT04514393	Not yet recruiting	Drug: Methotrexate\|Drug: Ibrutinib\|Drug: Temozolomide	Primary Central Nervous System Lymphoma\|PCNSL\|Non Hodgkin Lymphoma	Huiqiang Huang\|Guangdong 999 Brain Hospital\|Nanfang Hospital of Southern Medical University\|Xian-Janssen Pharmaceutical Ltd.\|Sun Yat-sen University	December 1 2020	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

よくある質問（FAQ）

質問1：
How to reconstitute the compound S2680 for in vivo studies?
回答：
For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

研究分野別

製品類型

Ibrutinib (PCI-32765)

文献中Selleckの製品使用例(411)

製品安全説明書

Target Protein Ligand阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Ibrutinib (PCI-32765) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技術サポート

よくある質問（FAQ）